Clinical Trial Update: An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B [Phase 1, Phase 2]

View source ↗

Summary

Open-label extension study of investigational fitusiran in adults with moderate to severe Hemophilia A or B; trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Fitusiran (fitusiran)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Hemophilia A, Hemophilia B | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-06-05